Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.

Background: Secondary to phasing out chlorofluorocarbons (CFCs), the fluticasone propionate (FP) pressurized metered-dose inhaler has been formulated in a nonozone-depleting propellant, hydrofluoralkane (HFA) 134a.

Objectives: To demonstrate equivalent efficacy and safety of FP 200 microg daily propelled by HFA 134a to FP 200 microg daily propelled by CFCs 11 and 12 over a four-week treatment period in pediatric asthmatic patients.

Methods: The study was multinational, randomized, double blind and of parallel group design.